We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

The New Frontiers of Nanobiotechnology

By Biotechdaily staff writers
Posted on 12 Sep 2003
Nanotechnology and medical biotechnology are interacting to create a new discipline called nanobiotechnology, which offers many new possibilities in disease detection, drug delivery, and imaging. According to a new report from Frost & Sullivan (London, UK), nano-enabled services could potentially represent up to US$180 billion annually in medicine and healthcare by 2015.

Nanostructured materials have been developed that can serve as templates for tissue replacement and enable better treatment of burns, while researchers are attempting to induce bone tissue growth through polymer templates. Developments in nanoencaspulation promise enhanced delivery and absorption of drugs, and carbon nanotubes are being contemplated as a system for delivery of gene therapy. Magnetic nanoparticles containing drugs could be delivered to specific parts of the body by means of a magnetic field.

Encouraging developments in microfluidics enable the modification of drug levels within the body in real-time, avoiding fluctuations in concentration. Nanosensors are being used to detect DNA sequences in the body, and implanted nanosensors could enable simpler and more-effective diagnosis. Noninvasive imaging technologies such as tensor magnetic resonance imaging are designed to allow doctors to better detect the development, degeneration, and disease of soft tissue. Quantum dots, which have the ability to bond chemically to biologic molecules and emit bright fluorescent light, could be effective in detecting early carcinoma.

"With a new generation of nanochips, we could obtain much more accurate medical diagnosis; quickly and efficiently screen the mind-boggling array of drug candidates, and perform targeted delivery of drugs and vaccines like never before,” said Girish Solank, an analyst with Frost and Sullivan.




Related Links:
Frost & Sullivan

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Thyroid Test
Anti-Thyroid EIA Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
12 Sep 2003  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
12 Sep 2003  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
12 Sep 2003  |   BioResearch